Loading the company…
Loading the company…
Families: Structural heart (TAVR, TEER).
All companies · Product and company coverage
In the last ten years FDA made 6 decisions for Jenavalve Technology (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (6). The latest was on 2026-10-13.
| Family | Decisions on record |
|---|---|
| Structural heart (TAVR, TEER) | 6 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-10-13 | PMA | P250024-S005 | Trilogy Transcatheter Heart Valve System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-10-07 | PMA | P250024-S006 | Trilogy Transcatheter Heart Valve System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-07-09 | PMA | P250024-S003 | Trilogy Transcatheter Heart Valve System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-05-18 | PMA | P250024-S001 |
| Trilogy Transcatheter Heart Valve System · Postapproval Study Protocol |
| 2026-05-18 | PMA | P250024-S002 | Trilogy Transcatheter Heart Valve System · Postapproval Study Protocol |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Jenavalve Technology.